Form D · Pharmaceuticals
NapaJen Pharma, Inc.
Burlingame, CA · CIK 0001883744
Offering snapshot reported Sep 17, 2021 · SEC filing
- Reported sold
- $500K Offering amount: $2M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 17, 2021 | Initial | $500,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-413786
Source: Form D, filed Sep 17, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Taro Inaba | Director |
| Kazuhiko Nonomura | Director |
| Walter Olesiak | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
533 Airport Boulevard, Suite 527
Burlingame, CA, 94010
Burlingame, CA, 94010